What is the appropriate dosing regimen for switching a perimenopausal woman from topical testosterone therapy to testosterone troches?

Dosing for Switching from Topical Testosterone to Troche in Perimenopausal Women

There is no established evidence-based protocol for switching from topical testosterone to troches in perimenopausal women, and compounded testosterone troches cannot be recommended due to lack of efficacy and safety data 1.

Critical Evidence Gaps

The 2019 Global Consensus Statement explicitly states that compounded "bioidentical" testosterone therapy, including troches, cannot be recommended for treatment unless an authorized equivalent preparation is not available 1. This is due to:

• Lack of evidence for efficacy and safety
• Variable quality and inconsistent dosing in compounded products
• No standardized manufacturing oversight

Guideline-Based Approach

If Switching is Necessary

The only appropriate approach is to use FDA-approved transdermal preparations (patches, gels, or creams) rather than troches 1, 2. The guidelines are clear that:

1. Transdermal non-oral preparations are preferred over oral formulations due to first-pass hepatic effects 1
2. Off-label use of male formulations is acceptable only if female-specific products are unavailable, provided testosterone levels remain in the physiologic female range 1
3. Compounded products should only be used when no approved product exists, and only from pharmacies compliant with Good Manufacturing Practice 1

Dosing Strategy When Transitioning

If you must transition from topical to any alternative testosterone formulation:

Step 1: Measure baseline testosterone

• Obtain morning total testosterone level while still on current topical therapy 1, 2

Step 2: Discontinue topical and initiate alternative

• If using approved transdermal products: Start with physiologic dosing (equivalent to 300 ng/dL testosterone level for premenopausal women) 1
• The goal is to approximate premenopausal physiologic concentrations, not supraphysiologic levels 1

Step 3: Monitor closely

• Check testosterone level at 3-6 weeks after initiating new formulation 1, 2
• Repeat every 6 months to screen for overuse and signs of androgen excess 1, 2
• Assess clinical response and signs of virilization (acne, hirsutism, voice changes) 1

Step 4: Titrate to physiologic range

• Target testosterone concentrations in the physiologic premenopausal female range (approximately 15-70 ng/dL total testosterone) 1
• Avoid supraphysiologic levels which increase adverse effects without additional benefit 1

Critical Caveats

Perimenopausal vs. Postmenopausal Women

The evidence base for testosterone therapy is limited to postmenopausal women with hypoactive sexual desire disorder (HSDD) 1, 2. For perimenopausal women specifically:

• No Level I evidence supports testosterone use in perimenopausal women 1, 3
• The only FDA indication (though no female product is approved) is for postmenopausal women with HSDD 1
• Limited research suggests potential benefit in late reproductive age women, but data are insufficient 3

Troches Specifically

Testosterone troches are oral formulations that carry specific concerns:

• Oral testosterone causes unfavorable lipid changes (increased LDL, decreased HDL) not seen with transdermal routes 4
• First-pass hepatic metabolism makes oral routes less desirable 1, 5
• Compounded troches lack quality control and standardized dosing 1

Safety Monitoring Requirements

Regardless of formulation:

• Discontinue if no benefit by 6 months 1
• Monitor for androgen excess: acne, hirsutism, voice deepening, clitoromegaly 1
• Safety data beyond 24 months are lacking 1
• Contraindicated in hormone-sensitive breast cancer 1

Practical Recommendation

Do not switch to troches. Instead, optimize the current transdermal regimen or switch to an alternative approved transdermal preparation (gel, cream, or patch) 1, 2. If the patient insists on troches despite counseling:

1. Document lack of evidence and potential risks
2. Use only if compounding pharmacy meets Good Manufacturing Practice standards 1
3. Start with lowest dose targeting physiologic levels
4. Monitor testosterone levels at 3-6 weeks, then every 6 months 1, 2
5. Reassess indication if patient is truly perimenopausal rather than postmenopausal 1, 3

The fundamental issue is that troches represent a compounded, non-evidence-based formulation with an oral route that is explicitly not recommended by current guidelines 1, 2.